CClinicalTrials.gg
CompletedNCT05852002Updated Jan 17, 2024

A Clinical Study of Pain and Discomfort Associated With Advanced Lung Cancer

An interventional study of 35 kDa hyaluronan fragment in Advanced Lung Cancer, sponsored by Nakhia Impex LLC. Completed at 1 site in Mongolia. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-01-17.

Sponsored by Nakhia Impex LLC · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

In this research, the patients with advanced lung cancer accompanied by pain and discomfort were treated by injecting freshly manufactured tissue permeable hyaluronan fragment HA35 into the tissue under abdominal adipose.

Read the detailed description

Pain is generally considered the most common symptom of lung cancer. The three most common causes of pain in patients with advanced lung cancer are: 1. metastasis of lung cancer to the bones, which accounts for approximately 34 percent of lung cancer pain; 2. Presence of a Pancoast tumor, located at the top of the lung close to the brachial plexus nerves and cervical sympathetic nerves, which accounts for approximately 31 percent of lung cancer pain; 3. Spread of the cancer into the chest wall, accounting for approximately 21 percent of lung cancer pain.

Palliative care is a specialized field that aims to alleviate symptoms and maximize the patient's quality of life. Palliative care does not focus on curing the disease or prolonging life, which is the goal of other cancer treatments, such as chemotherapy. However, palliative care is an important part of the patient's treatment plan and encompasses physical symptoms, psychosocial distress, spiritual distress, and caregiver distress.

The management of pain due to lung cancer may include a combination of medications, such as non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, opioids (pain medications), and antidepressants. For metastases to the bone, radiation therapy and the use of bisphosphonates (drugs to help prevent bone breakdown) can alleviate pain. In addition, smoking cessation (stopping smoking) is recommended, as surveys have revealed that lung cancer patients who continue to smoke after diagnosis have a higher incidence of pain and other lung cancer complications than nonsmokers and those who quit smoking.

While pain is the most common symptom of lung cancer, other symptoms include: persistent coughing,wheezing,shortness of breath,hoarseness,weight loss,loss of appetite,fatigue or feeling weak and respiratory infections (like bronchitis or pneumonia) that don't go away or keep returning.

Hyaluronidase PH20 produced 35 kDa tissue permeable low molecular weight hyaluronan fragment by cutting high molecular hyaluronan. The previous clinical studies had shown that local injection of 35 kDa hyaluronan fragment effectively relieved inflammatory pain and neuropathic pain and promoted chronic wound healing.

02

Conditions studied

  • Advanced Lung Cancer

Browse trials for

Keywords

  • 35kDa hyaluronan fragment
  • palliative care
  • pain and discomfort
  • cough
  • fatigue
03

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age>=18 years old
  • Sign the informed consent form voluntarily.
  • Expected survival ≥3 months.
  • Pathologically confirmed locally advanced, metastatic or recurrent non-small cell lung cancer (NSCLC), which is currently not suitable for local treatment such as radical surgery or radiotherapy.
  • The subject has good compliance and cooperates with the follow-up.

Exclusion criteria

Exclusion Criteria:

  • Subjects who are receiving systematic steroid treatments before the first cell treatment.
  • Subjects with a history of mental disorders or drug abuse that may influence treatment compliance.
  • Women in pregnancy or lactation or are expected to be pregnant during the study.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    35 kDa hyaluronan fragment injection

    35kDa hyaluronan fragment was produced by using hyaluronidase PH20 to cleave 1600kDa hyaluronan ( HA1600 ). Batch number of 35 kDa hyaluronan fragment injection is L20200708MP07707,and the injection was approved by Ministry of Health, Mongolia.

    Drug: 35 kDa hyaluronan fragment

Interventions

  • Drug35 kDa hyaluronan fragment

    100 mg of 35kDa hyaluronan fragment was injected deeply into abdominal fat layer once a day for 28 consecutive days.

    Also known as: B-HA

05

What researchers measure

Primary outcomes

  1. A pain scale

    0 represents no pain or discomfort , while 10 represents the most serious pain or discomfort.

    Time frame: twenty eight days

  2. Respiratory symptom cough

    A modified pain scale was used to assess respiratory symptom cough associated with advanced lung cancer. 0 represents no cough while 10 represents the most severe cough.

    Time frame: twenty eight days

  3. Fatigue

    A modified pain scale was used to assess fatigue associated with advanced lung cancer. 0 represents no fatigue while 10 represents the most severe fatigue.

    Time frame: twenty eight days

  4. The degree of facial skin brightness and facial expression or spirit

    A modified pain scale was used to assess the degree of facial skin brightness and facial expression or spirit associated associated with advanced lung cancer. 0 represents the best degree of facial skin brightness while 10 represents the worst degree of facial skin brightness; 0 represents the best degree of facial expression or spirit while 10 represents the worst degree of facial expression or spirit.

    Time frame: twenty eight days

  5. chest CT scans

    namely "significant reduction" or "significant increase" or "no significant changes" in lung tumor mass.

    Time frame: 3 months

06

Study locations

1 site
  • Mongolian National University of Medical Sciences
    Ulaanbaatar, Mongolia
07

Registry details

Key details

Study ID
NCT05852002
Lead sponsor
Nakhia Impex LLC
Collaborators
Mongolian National University of Medical Sciences
Responsible party
Sponsor
First posted
May 10, 2023
Start date
Apr 11, 2023
Primary completion
Nov 1, 2023
Completion
Dec 12, 2023
Last update
Jan 17, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion